文献速递关节外科创伤骨科

载酪醇和抗生素水凝胶的植入物涂层能否有效减少痤疮皮肤杆菌(原痤疮丙酸杆菌)生物膜形成?一项初步体外研究

Is Implant Coating With Tyrosol- and Antibiotic-loaded Hydrogel Effective in Reducing Cutibacterium (Propionibacterium) acnes Biofilm Formation? A Preliminary In Vitro Study.
PubMed 文献 · Clin Orthop Relat Res · 2019-01-01

该体外研究评估酪醇对痤疮皮肤杆菌浮游生长的抑制与清除、与利福平的协同作用,以及载酪醇、利福平或万古霉素水凝胶涂层减少钛合金盘生物膜形成的效果。结果显示酪醇对浮游菌有抑制和杀灭作用,与利福平呈相加作用;但载酪醇水凝胶涂层未减少生物膜,而可溶性酪醇在597 mg/mL(1 M)时抑制生物膜超过80%阈值。

要点

  • 酪醇对痤疮皮肤杆菌浮游生长的MIC为63 mM(9 mg/mL),MBC为250 mM(35 mg/mL)。
  • 酪醇与利福平的分数抑制浓度指数为0.56,棋盘法显示相加作用。
  • 载酪醇水凝胶涂层未减少生物膜形成,而可溶性酪醇在597 mg/mL(1 M)时抑制生物膜超过80%阈值。

核心结论

  • 植入物水凝胶涂层(单纯或补充抗菌剂)在体外未减少痤疮皮肤杆菌生物膜形成,但可溶性酪醇在597 mg/mL(1 M)时超过80%的生物膜抑制有意义阈值。

研究设计与样本

  • 体外研究,采用微量稀释法测定MIC和MBC、棋盘法评估协同作用、XTT法评估浮游菌活力、结晶紫染色评估钛合金盘生物膜形成,每种测试条件分配16个钛合金盘。

主要发现

  • 酪醇抑制痤疮皮肤杆菌浮游生长的MIC为63 mM(9 mg/mL),MBC为250 mM(35 mg/mL)。
  • 酪醇与利福平的分数抑制浓度指数为0.56,棋盘法显示相加作用。
  • 载酪醇水凝胶在MIC浓度下抑制浮游菌与对照组无差异,中位吸光度0.21(IQR 0.19-0.24)vs 0.26(IQR 0.23-0.31),p=0.066。
  • 载酪醇水凝胶在597 mg/mL(1 M)浓度下减少生物膜与对照组无差异,中位吸光度0.12(IQR 0.11-0.13)vs 0.14(IQR 0.12-0.16),p=0.076。
  • 可溶性酪醇在597 mg/mL(1 M)浓度下抑制生物膜优于对照组,中位吸光度0.11(IQR 0.09-0.13)vs 0.13(IQR 0.12-0.14),p=0.007。

关键数值与推荐

  • 酪醇对痤疮皮肤杆菌的MIC为63 mM(9 mg/mL),MBC为250 mM(35 mg/mL)。
  • 酪醇与利福平的分数抑制浓度指数为0.56,判定为相加作用。
  • 可溶性酪醇在597 mg/mL(1 M)时超过80%的生物膜抑制有意义阈值。

临床怎么用

  • 作者认为,当前临床前研究结果不支持使用快速生物可吸收水凝胶作为对抗痤疮皮肤杆菌生物膜的涂层方法。
  • 作者建议,未来动物研究应进一步测试直接局部给予高浓度可溶性酪醇。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies have suggested that Cutibacterium acnes (formerly known as Propionibacterium) is the most frequently isolated pathogen after shoulder arthroplasty. To address the burden of periprosthetic joint infections associated with this pathogen, new prevention methods are needed. Tyrosol has a promising record of effectiveness in the field of biofilm-associated infections; however, to our knowledge, it has not been tested against C. acnes thus far. QUESTIONS/PURPOSES: In this in vitro study, we asked: (1) Is tyrosol effective in inhibiting and eradicating C. acnes planktonic growth? (2) Is there synergy between tyrosol and rifampicin? (3) Is supplementation of hydrogel with tyrosol at the minimum inhibitory and subinhibitory concentrations efficacious in reducing free-floating C. acnes growth? (4) Is implant hydrogel coating (either alone or combined with tyrosol, rifampicin, or vancomycin) beneficial in reducing C. acnes biofilm formation? (5) Is the administration of soluble tyrosol an effective measure against C. acnes biofilm formation? METHODS: We assessed C. acnes planktonic growth and eradication by inspecting visually the results of the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays. We also evaluated macroscopically the presence of synergy among tyrosol and rifampicin by means of the MIC checkerboard testing. Thereafter, we addressed colorimetrically the efficacy of tyrosol-loaded Defensive Antibacterial Coating (DAC®) hydrogel against the C. acnes free-floating form by means of the XTT cell proliferation reduction assay. Then, we explored photometrically the effect of hydrogel and soluble tyrosol at reducing C. acnes biofilm formation on titanium alloy disks that simulated orthopaedic implants by using the minimum biofilm inhibition concentration assay. In particular, 16 disks were sequentially allocated to each of the following testing conditions: (1) hydrogel alone; (2) tyrosol-loaded hydrogel; (3) rifampicin-supplemented hydrogel; (4) vancomycin-loaded hydrogel; and (5) soluble tyrosol. Subsequently, implants were sonicated and cell viability was evaluated in terms of the XTT assay. RESULTS: Tyrosol was effective in inhibiting C. acnes planktonic (free-floating) growth demonstrating MIC values of 63 mM (9 mg/mL) and MBC values of 250 mM (35 mg/mL). Concerning synergy assessment, the checkerboard testing revealed additivity among tyrosol and rifampicin with a fractional inhibitory concentration index of 0.56. In addition, a hydrogel coating with tyrosol at the MIC showed no difference in the inhibition of free-floating C. Acnes form over control (median absorbance [MA] for tyrosol-supplemented hydrogel versus control groups were 0.21 [interquartile range {IQR}, 0.19-0.24] versus 0.26 [IQR, 0.23-0.31], p = 0.066). Furthermore, loaded hydrogel with tyrosol at 597 mg/mL (1 M) was no more effective than control in reducing C. acnes biofilm formation (MAs for tyrosol versus control were 0.12 [IQR, 0.11-0.13] versus 0.14 [IQR, 0.12-0.16], respectively; p = 0.076). This was also the case when we considered hydrogel in conjunction with vancomycin and rifampicin (MAs for vancomycin at 2% and 5% and rifampicin at 1% versus biofilm control were 0.139 [IQR, 0.133-0.143] and 0.141 [IQR, 0.133-0.143] and 0.135 [IQR, 0.128-0.146] versus 0.142 [IQR, 0.136-0.144], correspondingly). In contrast, soluble tyrosol at 597 mg/mL (1 M) inhibited biofilm formation compared to control (MAs for tyrosol and control groups were 0.11 [IQR, 0.09-0.13] versus 0.13 [IQR, 0.12-0.14], p = 0.007). CONCLUSIONS: Although the implant coating with hydrogel (either pure or supplemented with antimicrobial agents) did not diminish C. acnes biofilm development in vitro, soluble tyrosol at 597 mg/mL (1 M) exceeded the meaningful biofilm inhibition threshold of 80%. CLINICAL RELEVANCE: The results of the current preclinical investigation did not support the use of a fast, bioresorbable hydrogel as a coating method against C. acnes biofilms. Instead, direct local administration of soluble tyrosol at high concentrations should be further tested in future animal studies.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Tsikopoulos K, Bidossi A, Drago L, et al. Is Implant Coating With Tyrosol- and Antibiotic-loaded Hydrogel Effective in Reducing Cutibacterium (Propionibacterium) acnes Biofilm Formation? A Preliminary In Vitro Study. Clin Orthop Relat Res. 2019. PMID: 31135555. doi:10.1097/CORR.0000000000000663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。